The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. - Balbino B; Herviou P; Godon O; Stackowicz J; Goff OR; Iannascoli B; Sterlin D; Brûlé S; Millot GA; Harris FM; Voronina VA; Nadeau KC; et al. (The Journal of clinical investigation, 2020)